The therapeutic community is abuzz with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s demonstrating significant promise in clinical trials for addressing obesity. Unlike some existing weight loss approaches, retatrutide appears to provide a more substantial decrease in body size and benefit metabolic function, par